These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17043161)

  • 1. Cardiovascular effects of nonproteolytic activation of prorenin.
    Susic D; Lippton H; Knight M; Frohlich ED
    Hypertension; 2006 Dec; 48(6):e113; author reply e114. PubMed ID: 17043161
    [No Abstract]   [Full Text] [Related]  

  • 2. Renin report: spotlight on Renin: therapeutic opportunities for Renin inhibitors.
    Hollenberg NK;
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):107-9. PubMed ID: 16470491
    [No Abstract]   [Full Text] [Related]  

  • 3. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract]   [Full Text] [Related]  

  • 4. Involvement of activated prorenin in the pathogenesis of slowly progressive nephropathy in the non-clipped kidney of two kidney, one-clip hypertension.
    Ryuzaki M; Ichihara A; Ohshima Y; Sakoda M; Kurauchi-Mito A; Narita T; Kinouchi K; Murohashi-Bokuda K; Nishiyama A; Itoh H
    Hypertens Res; 2011 Mar; 34(3):301-7. PubMed ID: 21107335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on renin: cardiovascular outcomes in chronic kidney disease and suppression of the renin-angiotensin system.
    Garcia-Donaire JA; Ruilope LM
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):56-8. PubMed ID: 17083074
    [No Abstract]   [Full Text] [Related]  

  • 6. Spotlight on renin: Nonproteolytic activation of prorenin by the (pro)renin receptor is blocked by decoy peptide.
    Suzuki F
    J Renin Angiotensin Aldosterone Syst; 2007 Jun; 8(2):101-3. PubMed ID: 17703437
    [No Abstract]   [Full Text] [Related]  

  • 7. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
    Sharkovska Y; Kalk P; Lawrenz B; Godes M; Hoffmann LS; Wellkisch K; Geschka S; Relle K; Hocher B; Stasch JP
    J Hypertens; 2010 Aug; 28(8):1666-75. PubMed ID: 20613628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renin, prorenin, and the direct renin inhibitor aliskiren].
    Slabý A; Zák A
    Cas Lek Cesk; 2010; 149(2):55-60. PubMed ID: 20662466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

  • 10. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC; Perazella MA
    Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.
    Epstein BJ; Leonard PT; Shah NK
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):713-25. PubMed ID: 22894628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide.
    Feldt S; Batenburg WW; Mazak I; Maschke U; Wellner M; Kvakan H; Dechend R; Fiebeler A; Burckle C; Contrepas A; Jan Danser AH; Bader M; Nguyen G; Luft FC; Muller DN
    Hypertension; 2008 Mar; 51(3):682-8. PubMed ID: 18212269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular biology in regulation of renal functions: Renin-angiotensin system].
    Takeuchi K; Ito S
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():187-91. PubMed ID: 16523885
    [No Abstract]   [Full Text] [Related]  

  • 14. Preventing and reversing target organ damage by treatment of the renin-angiotensin system.
    Krakoff LR; Rajasekharaiah V
    Mt Sinai J Med; 1998 Mar; 65(2):125-32. PubMed ID: 9520516
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II.
    Saris JJ; 't Hoen PA; Garrelds IM; Dekkers DH; den Dunnen JT; Lamers JM; Jan Danser AH
    Hypertension; 2006 Oct; 48(4):564-71. PubMed ID: 16940215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin and prorenin activate pathways implicated in organ damage in human mesangial cells independent of angiotensin II production.
    Melnyk RA; Tam J; Boie Y; Kennedy BP; Percival MD
    Am J Nephrol; 2009; 30(3):232-43. PubMed ID: 19451703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for cardiovascular effects of prorenin.
    Sealey JE
    J Hum Hypertens; 1995 Jun; 9(6):381-4. PubMed ID: 7473514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases!
    Waeber B
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):216. PubMed ID: 22389390
    [No Abstract]   [Full Text] [Related]  

  • 20. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases.
    Politi A; Durdagi S; Moutevelis-Minakakis P; Kokotos G; Papadopoulos MG; Mavromoustakos T
    Eur J Med Chem; 2009 Sep; 44(9):3703-11. PubMed ID: 19410337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.